VYNE Therapeutics

VYNE

Market cap $25.4M

VYNE Hedge Fund Activity: Q1 2026 in Review

45 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in VYNE Therapeutics (VYNE) for Q1 2026, worth a combined $8.63M — up 81% from $4.77M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new VYNE positions and 5 closed out — a net gain of 3 holders — while 11 added to existing stakes and 5 trimmed.

The largest buyer was Lynx1 Capital Management, opening a new position worth an estimated $950K. The largest seller was Acadian Asset Management, cutting an estimated $150K.

• 45 institutional investors held VYNE Therapeutics (VYNE) as of Q1 2026, up from 44 in Q4 2025.
• Funds reported $8.63M of VYNE Therapeutics stock for Q1 2026, up 81% quarter-over-quarter.
• 8 funds opened new VYNE Therapeutics positions in Q1 2026 and 5 closed out, a net change of +3 holders.
• The largest VYNE Therapeutics buyer in Q1 2026 was Lynx1 Capital Management, an estimated $950K added.
• The largest VYNE Therapeutics seller in Q1 2026 was Acadian Asset Management, an estimated $150K sold.

Based on aggregated 13F filings for Q1 2026.